A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.

Abstract

4014 Background: The prognosis for AGC patients failing 1st line treatment is poor. FGFR2 amplification occurs in ~5-10% and polysomy in > 20% of gastric cancers (GCs). AZD is a selective FGFR1-3 i...